These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 15704058)

  • 21. Endothelin antagonism with bosentan: a review of potential applications.
    Roux S; Breu V; Ertel SI; Clozel M
    J Mol Med (Berl); 1999 Apr; 77(4):364-76. PubMed ID: 10353441
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bosentan: a dual endothelin receptor antagonist.
    Rubin LJ; Roux S
    Expert Opin Investig Drugs; 2002 Jul; 11(7):991-1002. PubMed ID: 12084009
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bosentan effects on hemodynamics and clinical outcome in heart failure patients with pulmonary hypertension awaiting cardiac transplantation.
    Hefke T; Zittermann A; Fuchs U; Schulte-Eistrup S; Gummert JF; Schulz U
    Thorac Cardiovasc Surg; 2012 Feb; 60(1):26-34. PubMed ID: 21432755
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hemodynamic and coronary effects of the endothelin antagonist bosentan in patients with coronary artery disease.
    Wenzel RR; Fleisch M; Shaw S; Noll G; Kaufmann U; Schmitt R; Jones CR; Clozel M; Meier B; Lüscher TF
    Circulation; 1998 Nov; 98(21):2235-40. PubMed ID: 9826308
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Short-term hemodynamic effects of endothelin receptor blockade in dogs with chronic heart failure.
    Shimoyama H; Sabbah HN; Borzak S; Tanimura M; Shevlyagin S; Scicli G; Goldstein S
    Circulation; 1996 Aug; 94(4):779-84. PubMed ID: 8772702
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical and hemodynamic effects of bosentan dose optimization in symptomatic heart failure patients with severe systolic dysfunction, associated with secondary pulmonary hypertension--a multi-center randomized study.
    Kaluski E; Cotter G; Leitman M; Milo-Cotter O; Krakover R; Kobrin I; Moriconi T; Rainisio M; Caspi A; Reizin L; Zimlichman R; Vered Z
    Cardiology; 2008; 109(4):273-80. PubMed ID: 17873492
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chronic endothelin receptor blockade prevents renal vasoconstriction and sodium retention in rats with chronic heart failure.
    Ding SS; Qiu C; Hess P; Xi JF; Clozel JP; Clozel M
    Cardiovasc Res; 2002 Mar; 53(4):963-70. PubMed ID: 11922906
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial.
    Galiè N; Rubin Lj; Hoeper M; Jansa P; Al-Hiti H; Meyer G; Chiossi E; Kusic-Pajic A; Simonneau G
    Lancet; 2008 Jun; 371(9630):2093-100. PubMed ID: 18572079
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of the dual endothelin receptor antagonist bosentan on Raynaud's phenomenon secondary to systemic sclerosis: a double-blind prospective, randomized, placebo-controlled pilot study.
    Nguyen VA; Eisendle K; Gruber I; Hugl B; Reider D; Reider N
    Rheumatology (Oxford); 2010 Mar; 49(3):583-7. PubMed ID: 20040526
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Endothelin receptor antagonists in heart failure--a refutation of a bold conjecture?
    Spieker LE; Lüscher TF
    Eur J Heart Fail; 2003 Aug; 5(4):415-7. PubMed ID: 12921801
    [No Abstract]   [Full Text] [Related]  

  • 31. Efficacy and safety of bosentan for pulmonary arterial hypertension in adults with congenital heart disease.
    Monfredi O; Griffiths L; Clarke B; Mahadevan VS
    Am J Cardiol; 2011 Nov; 108(10):1483-8. PubMed ID: 21943933
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study.
    Sitbon O; Badesch DB; Channick RN; Frost A; Robbins IM; Simonneau G; Tapson VF; Rubin LJ
    Chest; 2003 Jul; 124(1):247-54. PubMed ID: 12853530
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial.
    Jaïs X; D'Armini AM; Jansa P; Torbicki A; Delcroix M; Ghofrani HA; Hoeper MM; Lang IM; Mayer E; Pepke-Zaba J; Perchenet L; Morganti A; Simonneau G; Rubin LJ;
    J Am Coll Cardiol; 2008 Dec; 52(25):2127-34. PubMed ID: 19095129
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of Bosentan on Claudication Distance and Endothelium-Dependent Vasodilation in Hispanic Patients With Peripheral Arterial Disease.
    De Haro J; Bleda S; Varela C; Esparza L; Acin F;
    Am J Cardiol; 2016 Jan; 117(2):295-301. PubMed ID: 26651453
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bosentan for the treatment of pulmonary arterial hypertension.
    Kenyon KW; Nappi JM
    Ann Pharmacother; 2003; 37(7-8):1055-62. PubMed ID: 12841819
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and doppler measures in patients with pulmonary arterial hypertension.
    Galiè N; Hinderliter AL; Torbicki A; Fourme T; Simonneau G; Pulido T; Espinola-Zavaleta N; Rocchi G; Manes A; Frantz R; Kurzyna M; Nagueh SF; Barst R; Channick R; Dujardin K; Kronenberg A; Leconte I; Rainisio M; Rubin L
    J Am Coll Cardiol; 2003 Apr; 41(8):1380-6. PubMed ID: 12706935
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of endothelin in the maintenance of blood pressure in conscious rats with chronic heart failure. Acute effects of the endothelin receptor antagonist Ro 47-0203 (bosentan).
    Teerlink JR; Löffler BM; Hess P; Maire JP; Clozel M; Clozel JP
    Circulation; 1994 Nov; 90(5):2510-8. PubMed ID: 7955209
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Initial experience with bosentan therapy in patients considered ineligible for heart transplantation because of severe pulmonary hypertension.
    Perez-Villa F; Cuppoletti A; Rossel V; Vallejos I; Roig E
    Clin Transplant; 2006; 20(2):239-44. PubMed ID: 16640533
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Additional hypotensive effect of endothelin-1 receptor antagonism in hypertensive dogs under angiotensin-converting enzyme inhibition.
    Donckier JE; Massart PE; Hodeige D; Van Mechelen H; Clozel JP; Laloux O; Ketelslegers JM; Charlier AA; Heyndrickx GR
    Circulation; 1997 Aug; 96(4):1250-6. PubMed ID: 9286956
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Potential benefit of bosentan therapy in borderline or less severe pulmonary hypertension secondary to idiopathic pulmonary fibrosis-an interim analysis of results from a prospective, single-center, randomized, parallel-group study.
    Tanaka Y; Hino M; Gemma A
    BMC Pulm Med; 2017 Dec; 17(1):200. PubMed ID: 29237441
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.